Redeyes’ long-term view of Dignitana is intact despite the flat sales progression.
We visited Poland with Eastnine last week ~EUR 200m to spend on acquisitions.
Penetration improves further, private jet deal possible in H2'24 OEM to drive ~20-30% EBIT growth in...
23% ARR growth: strong new sales, with churn and uplift weaker.
Redeye comments on Tango Therapeutics' discontinuation of the USP1 programme (TNG348), which does no...
CEO highlighted the UK as a springboard for international growth Potential to add more user groups P...
Under de senaste åren har Zoomability investerat i verksamheten för att kunna exekvera på Bolagets t...
This morning ChromoGenics has received an offer from Färna Invest of SEK10 in cash per share.
Starkt kvartal över förväntan Under kv1 2024 levererade Fable Media en nettoomsättning i linje med...
Beyond Frames reported sales that were twice as high as our expectations for the quarter.
ExpreS2ion Biotechnologies gör framsteg i processen att inleda studier på människa med bröstcancerva...
Björn Borg (“Björn Borg”, “the Company” or “the Group”) is a well-established and renowned company w...
Redeye gives its initial comments on the news flow from Fragbite Group earlier this morning, where F...
Redeye's first comments on the Q1 report this morning.
23% y-o-y ARR growth in Q1, adj. EBITDA of DKK -3.7m "One-off" headwinds in Q1 means unchanged FY'24...
Cell impact visade som väntat fortsatt en rörelseförlust under kvartalet och negativa kassaflöden.
Redeye saw a sales development that was stronger than expected.
Ökat fokus på nya projekt Carlsquare Equity Research ser den nya influensasatsningen som en lovande ...
Redeye comments on Northbaze Q1 2024 report. EBITDA margin was good.
NoHo Partners hosted a CMD yesterday, where it talked about its new strategy and long-term targets f...
